By Stephen Nakrosis 
 

Celgene Corp. (CELG) said Monday results from the phase 3 STYLE study showed Otezla achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician's Global Assessment response after 16 weeks when compared with a placebo.

Otezla is for use by patients with moderate to severe plaque psoriasis.

The company also said statistical significance was met for the secondary endpoint of the whole body itch numeric rating scale at week 16.

Terrie Curran, president of Celgene's inflammation and immunology operations, said the company was "encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the Otezla label."

Celgene said the safety profile was generally consistent with the known safety profile of Otezla, and no new safety signals were identified in the trial.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

October 08, 2018 17:29 ET (21:29 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Celgene Charts.